Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Oct 12 · above the Ichimoku cloud · RSI 58 · MACD above its signal
None of the 29 investors followed here reported a position in 1066.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1066.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Cong (Rinan)Chief Executive Officer | — | 200K | — |
| Dec 30, 2025 | Long (Jing)Chairman of the Board | — | 480K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.4 | 1.8 | -26.3 | -8.3 | -2.3 | -5.7 | 6.0 | -4.3 | 3.6 | 1.2 | −32.9% | ||
| 2025 | 6.3 | 4.1 | 17.6 | -4.2 | -1.8 | 8.9 | 13.1 | -15.1 | -1.0 | -6.5 | 2.2 | -9.5 | +9.6% |
| 2024 | -34.2 | 1.6 | -4.1 | 9.4 | -14.6 | -18.4 | 6.2 | 11.6 | 27.4 | -13.7 | -7.2 | 1.8 | −39.8% |
| 2023 | 1.4 | -2.6 | -0.9 | 6.4 | -13.2 | -11.6 | -2.0 | -22.3 | -11.8 | 5.4 | 2.2 | 2.7 | −40.6% |
| 2022 | -2.0 | 12.8 | -22.0 | 0.5 | 3.3 | 4.7 | 7.5 | 9.2 | -1.3 | 2.5 | 4.8 | 13.1 | +31.8% |
| 2021 | -17.1 | -8.1 | 15.2 | 13.6 | -1.6 | 5.7 | -23.2 | -8.0 | 8.7 | -4.7 | -16.9 | -11.7 | −44.4% |
| 2020 | 43.5 | 8.1 | -2.4 | 20.6 | 14.7 | 27.1 | 14.3 | -8.1 | -14.7 | -3.0 | 7.1 | 9.1 | +170.3% |
| 2019 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2018 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2017 | -1.7 | -8.3 | 19.1 | 2.0 | 7.9 | 0.2 | 2.8 | -0.8 | -11.5 | 1.3 | 15.6 | 0.0 | +25.0% |
| 2016 | -6.9 | 0.8 | -1.2 | -5.5 | -4.5 | -1.1 | -1.8 | 15.9 | 3.6 | -2.7 | 5.9 | -3.4 | −2.8% |
| 2015 | -2.7 | 4.9 | 6.9 | 5.1 | -4.9 | -15.2 | -10.2 | 4.2 | -10.0 | 10.2 | 2.2 | -3.1 | −14.9% |
| 2014 | -13.0 | 8.8 | -10.7 | -11.8 | -3.3 | 0.4 | 6.3 | -2.5 | -2.2 | 1.8 | -12.1 | -8.9 | −40.2% |
| 2013 | -3.0 | -3.6 | -2.5 | 6.0 | 30.3 | -12.7 | -13.6 | -0.3 | 4.1 | -4.3 | 45.3 | -1.1 | +35.7% |
| 2012 | 2.1 | 8.4 | 14.6 | 1.1 | -11.3 | 7.3 | 1.3 | -1.3 | 17.3 | 4.6 | -23.6 | -3.7 | +10.3% |
| 2011 | -8.4 | -5.0 | 15.6 | -4.1 | -3.3 | 8.9 | -5.0 | -8.0 | -10.7 | -6.7 | -20.1 | 7.0 | −36.6% |
| 2010 | 9.7 | 5.6 | 8.0 | 12.5 | -18.4 | 15.0 | 1.6 | 11.7 | 13.9 | -7.0 | 3.9 | 3.3 | +70.3% |
| 2009 | 13.1 | -1.8 | 5.7 | 6.1 | 26.9 | 7.1 | 2.0 | 3.4 | 21.9 | 7.6 | -0.5 | -5.5 | +120.2% |
| 2008 | -26.9 | -8.1 | -23.5 | 35.0 | 2.4 | -11.9 | -6.7 | 14.1 | -4.2 | -20.0 | 19.6 | 6.9 | −34.7% |
| 2007 | 23.3 | 12.2 | 14.4 | 5.8 | 7.2 | 19.6 | 10.5 | -14.1 | 18.8 | -13.8 | 8.0 | -3.1 | +118.4% |
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company offers medical device products, including safe infusion, clinical nursing, perioperative, endocrine, urinary, rehabilitation system, and extracorporeal circulation solutions; pharma packaging products comprising prefilled drug delivery system, pharmaceutical packaging consumables, and automatic drug delivery systems; and orthopedic products that include spine, joint, trauma, sports medicine, bone repair material, and spinal endoscope products, as well as orthopedic devices, PRP treatment consumables, and negative pressure drainage consumables. It also provides interventional products, such as tumor, vascular, and nursing interventions, as well as blood management products, including whole blood collection consumables and blood transfusion equipment. In addition, the company manufactures and sells medical PVC granules, plastic packing bags, and carton boxes; manufacture and sale of medical polymer materials and products; injection puncture instruments; computer technical services; and X-ray based irradiation machines. Further, it provides finance leasing, factoring, and consulting services. The company was founded in 1988 and is based in Weihai, the People's Republic of China.
Buy / hold / sell counts
No recent headlines.